Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Nov 2026, 03:15 UTC
2878
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
546
Lead sponsors
across recruiting studies
Top sites
London 2026 Manchester 676 Birmingham 483 Glasgow 436 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC97 Hoffmann-La Roche82 Novartis Pharmaceuticals72 Janssen Research & Development, LLC70
Site city
London2026 Manchester676 Birmingham483 Glasgow436 Cambridge425
All 437 cities
Target enrolment
to

Trials with a site in London

2026 of 2878 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
By invitation
Sarepta Therapeutics, Inc.
Phase 1/2
78
London, Nottingham, Southampton
2024-03-04
Recruiting
Takeda
Phase 3
50
London
2024-03-01
Active, closed
Acumen Pharmaceuticals
Phase 2
542
London, Winchester, Motherwell, Preston, Guildford, Sheffield, Bristol
2024-02-29
Active, closed
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Glasgow, Newcastle upon Tyne, London
2024-02-28
Recruiting
Daiichi Sankyo
Phase 2/3
860
Bath, Glasgow, Headington, London, Northampton
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Cambridge, Coventry, London, Nottingham
2024-02-26
Recruiting
Pulmonx Corporation
Not applicable
200
London
2024-02-22
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
London, Glasgow, Manchester, Sutton
2024-02-21
Active, closed
ViiV Healthcare
Phase 3
463
Glasgow, London
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
London, Manchester
2024-02-20
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
Glasgow, London, Salford, Sheffield
2024-02-20
Recruiting
Amicus Therapeutics
Observational
500
Birmingham, Cambridge, Cardiff, London, Manchester, Salford
2024-02-16
Active, closed
Boehringer Ingelheim
Phase 3
428
Edinburgh, Leicester, London, Sutton
2024-02-09
Recruiting
Pfizer
Phase 3
492
Milton Keynes, Bodelwyddan, Bournemouth, Poole, Eastbourne, Worthing, Birmingham, London
2024-02-08
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Aberdeen, Birmingham, Boston, Bradford, Liverpool, London, Newport
2024-02-05
Active, closed
Genmab
Phase 3
1,095
Plymouth, London, Portsmouth, Leeds, Manchester, Newcastle upon Tyne
2024-02-05
Active, closed
Autolus Limited
Phase 1
16
Cambridge, London, Manchester
2024-02-02
Active, closed
ReCode Therapeutics
Phase 2
128
Birmingham, Cambridge, Leeds, London, Nottingham, Southampton
2024-02-01
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
NCT06553625Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
Boston Scientific Corporation
Observational
200
London
2024-01-29
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
London, Manchester, Sutton
2024-01-25
Active, closed
BicycleTx Limited
Phase 2
375
Bristol, Cambridge, London, Plymouth, Sutton
2024-01-24
Recruiting
Ascendis Pharma A/S
Phase 2
72
London
2024-01-23
Active, closed
Sanofi
Phase 3
260
Cardiff, London, Leeds, Manchester, Newcastle upon Tyne
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Active, closed
Pfizer
Phase 3
394
London
2024-01-19
Active, closed
Bolt Medical
Not applicable
426
Harefield, London
2024-01-19
Active, closed
DualityBio Inc.
Phase 3
541
Truro, London, Southampton, Manchester, Maidstone, Middlesex, Nottingham, Bath
2024-01-18
Active, closed
Regeneron Pharmaceuticals
Observational
11
Southampton, London
2024-01-17
Active, closed
Janssen Research & Development, LLC
Phase 3
774
London, Reading, Salford, Southampton
2024-01-17
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
98
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Birmingham, Cardiff, Glasgow, Hexham, London, Manchester
2024-01-11
Active, closed
Pfizer
Phase 2
333
London
2024-01-09
Active, closed
RECORDATI GROUP
Phase 2
93
Bristol, London
2024-01-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
London
2024-01-03
By invitation
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
BioMarin Pharmaceutical
Phase 1/2
18
London
2024-01-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Cambridge, Gloucester, Lincoln, Boston, London, Gwent, Windsor, Manchester
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Cambridge, Truro, Glasgow, London, Manchester
2023-12-31
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
London, Manchester, Surrey
2023-12-29
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Birmingham, London, Salford
2023-12-28
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
London, Oxford, Southhampton
2023-12-27
Active, closed
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Active, closed
Affera Global Registry
NCT06026345Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
540
Cambridge, London
2023-12-22
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
London, Manchester, Salford
2023-12-20
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
London, Manchester, Nottingham
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
London, Oxford
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
Danon Disease Natural History Study
NCT06214507Danon Disease
Rocket Pharmaceuticals Inc.
Observational
60
London
2023-12-20
Recruiting
Improving CRT Outcome With Non-Invasive Cardiac Mapping
NCT05564793Heart Failure With Reduced Ejection Fraction
EP Solutions SA
Not applicable
330
London, Oxford
2023-12-20
Recruiting
Nykode Therapeutics ASA
Phase 1/2
110
London
2023-12-19
Recruiting
Janssen-Cilag Ltd.
Observational
900
Birmingham, London, Wolverhampton
2023-12-18
Active, closed
Hoffmann-La Roche
Phase 1
70
London
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
London, Nottingham, Torquay
2023-12-18
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
London, Portsmouth, Canterbury, Central Middlesbrough
2023-12-15
Recruiting
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Recruiting
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
London, Leeds
2023-12-13
Active, closed
Taysha Gene Therapies, Inc.
Phase 1/2
6
London
2023-12-12
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
DrugGB-0895
Generate Biomedicines
Phase 1
156
London, Manchester, Merthyr Tydfil
2023-12-12
Recruiting
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
London
2023-12-08
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Active, closed
Aura Biosciences
Phase 3
108
London, Sheffield
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Active, closed
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Active, closed
AstraZeneca
Phase 1/2
55
Cambridge, London, Manchester
2023-12-05
Recruiting
Elios Vision, Inc.
Not applicable
194
East Grinstead, Edinburgh, Guildford, London, Manchester
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Active, closed
AnaptysBio, Inc.
Phase 2
132
Belfast, Cambridge, Liverpool, London, Runcorn, Shrewsbury, York
2023-12-04
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne
2023-12-01
Active, closed
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
Active, closed
Hoffmann-La Roche
Phase 2
13
London, Oxford
2023-11-29
Active, closed
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
BioMarin Pharmaceutical
Observational
400
London, Glasgow
2023-11-27
Active, closed
GlaxoSmithKline
Phase 1
127
Blackpool, Harrow, Barnsley, Cambridge, Cannock, London, Manchester, West Yorkshire
2023-11-27
Active, closed
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
London
2023-11-24
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
London, Edinburgh
2023-11-20
Recruiting
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Torquay, Truro
2023-11-16
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Recruiting
Autolus Limited
Phase 1
30
London, Manchester, Newcastle upon Tyne
2023-11-16
Active, closed
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Sutton, London
2023-11-14
Recruiting
Leucid Bio
Phase 1/2
17
London, Manchester
2023-11-13
Recruiting
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Active, closed
Xentria, Inc.
Phase 1/2
32
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Liverpool, London, Newcastle upon Tyne
2023-11-10
Active, closed
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
Pfizer
Phase 3
1,571
Isleworth, Southampton, London
2023-11-08
Active, closed
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
AstraZeneca
Phase 3
1,835
Cardiff, Dundee, Glasgow, London, York
2023-11-07
Active, closed
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
London
2023-11-06
By invitation
Edgewise Therapeutics, Inc.
Phase 2
260
Salford, London, Newcastle
2023-11-02
Active, closed
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Edinburgh, London
2023-10-26
Active, closed
Summit Therapeutics
Phase 3
1,600
Leeds, London, Manchester
2023-10-26
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Birmingham, Blackpool, Bury St Edmunds, Colchester, London, Truro
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth
2023-10-23
Recruiting
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Active, closed
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Active, closed
Genentech, Inc.
Phase 2
260
Liverpool, Belfast, Birmingham, Cambridge, London
2023-10-18
Recruiting
W.L.Gore & Associates
Not applicable
244
Canterbury, London, Southampton
2023-10-17
Active, closed
Celgene
Phase 3
79
Birmingham, London
2023-10-16
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Harrow, London, Reading, Salford
2023-10-12
Recruiting
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
Active, closed
Clinuvel, Inc.
Phase 3
200
London, Manchester
2023-10-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
By invitation
Biogen
Phase 3
306
London, Birmingham, Chapel Allerton
2023-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Recruiting
AbbVie
Phase 3
90
London
2023-10-02
Recruiting
Abbott Medical Devices
Observational
1,000
London, Middlesbrough, Stoke-on-Trent, Wolverhampton
2023-09-29
By invitation
Sarepta Therapeutics, Inc.
Phase 3
400
London, Oxford, Newcastle upon Tyne
2023-09-27
Active, closed
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
London
2023-09-22
Active, closed
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
By invitation
Denali Therapeutics Inc.
Phase 2/3
99
Birmingham, London, Manchester
2023-09-20
Active, closed
Bayer
Phase 1
85
Cambridge, London, Sutton
2023-09-20
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
London
2023-09-15
Active, closed
Hoffmann-La Roche
Phase 3
687
Edinburgh, London
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Wakefield, Birmingham, Leeds, London, Portsmouth
2023-09-13
By invitation
argenx
Phase 3
240
Liverpool, London, Salford
2023-09-12
Recruiting
Biotest
Phase 3
590
Plymouth, London, Glasgow, Guildford, Cardiff
2023-09-09
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Birmingham, Cambridge, Liverpool, London, Manchester, Preston
2023-09-07
Recruiting
Rocket Pharmaceuticals Inc.
Phase 2
18
London
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Leicester, London
2023-09-01
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Birmingham, Glasgow, London
2023-08-31
By invitation
Disc Medicine, Inc
Phase 2/3
230
London, Dundee, Salford
2023-08-31
Active, closed
AnaptysBio, Inc.
Phase 2
420
London, Manchester
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
Dundee, Glasgow, Liverpool, London, Oxford
2023-08-31
By invitation
CSL Behring
Observational
56
London, Cambridge, Southampton
2023-08-30
Active, closed
Pharming Technologies B.V.
Phase 3
16
London
2023-08-30
Recruiting
AviadoBio Ltd
Phase 1/2
18
Cambridge, Cardiff, London
2023-08-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
AstraZeneca
Observational
52,121
London
2023-08-21
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Glasgow, London
2023-08-16
Active, closed
Apreo Health, Inc.
Not applicable
30
London
2023-08-15
By invitation
Vertex Pharmaceuticals Incorporated
Phase 3
174
Cardiff, London
2023-08-11
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
347
Leicester, London, Newcastle
2023-08-10
Recruiting
Novian Health Inc.
Not applicable
122
London, Oxford
2023-08-09
Active, closed
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Recruiting
ADARx Pharmaceuticals, Inc.
Phase 1/2
50
London
2023-08-07
Active, closed
Praxis Precision Medicines
Phase 2/3
77
Glasgow, London
2023-08-02
Recruiting
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Barnet, London, Manchester, Nottingham
2023-07-31
Active, closed
Belite Bio, Inc
Phase 3
429
Great Yarmouth, Harrow, London
2023-07-27
Active, closed
AbbVie
Phase 3
1,014
Bretton, London, Southampton, Northampton, Londonderry, Luton, Portsmouth
2023-07-25
Recruiting
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Active, closed
AC Immune SA
Phase 2
150
London, Salford
2023-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Recruiting
Amicus Therapeutics
Phase 3
36
London
2023-07-18
Recruiting
Lung cAncer Robotic Comparative Study
NCT06038227Lung Cancer
Intuitive Surgical
Observational
600
Bristol, Coventry, London
2023-07-15
Active, closed
Mineralys Therapeutics Inc.
Phase 3
1,076
Newquay, Fowey, Glasgow, Chippenham, Cambridge, Carshalton, London, Plymouth
2023-07-14
Active, closed
Minoryx Therapeutics, S.L.
Phase 3
40
London
2023-07-12
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Dundee, London, Metropolitan Borough of Wirral, Oxford
2023-07-11
By invitation
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT05697861Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Intellia Therapeutics
Observational
72
London
2023-07-10
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
2023-07-06
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
By invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
NCT05872022Pregnancy, Obesity, Overweight
Novo Nordisk A/S
Observational
728
London
2023-07-05
Recruiting
Amgen
Phase 2
15
London, Birmingham
2023-07-03
Active, closed
Celestra Health Systems
Observational
90
London
2023-07-01
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
London, Manchester
2023-06-30
Active, closed
Takeda
Observational
50
London
2023-06-29
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham
2023-06-28
Active, closed
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
36
Cambridge, London
2023-06-27
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Birmingham, London, Salford
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Oxford, London
2023-06-27
Active, closed
Alumis Inc
Phase 2
408
Leeds, London, Southampton
2023-06-26
Active, closed
Viatris Innovation GmbH
Phase 3
451
Leicester, London
2023-06-26
Active, closed
Swedish Orphan Biovitrum
Observational
165
London
2023-06-26
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
390
London
2023-06-23
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
Active, closed
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
Basildon, London, Taunton
2023-06-21
By invitation
Ascendis Pharma Growth Disorders A/S
Phase 2/3
140
London
2023-06-21
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Glasgow, London
2023-06-20
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
NCT05967143Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Sirtex Medical
Observational
845
Manchester, London
2023-06-19
Active, closed
RHEACELL GmbH & Co. KG
Phase 3
91
London
2023-06-13
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York
2023-06-13
Active, closed
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
AbbVie
Phase 1
135
Cambridge, Leicester, London
2023-06-09
Recruiting
H. Lundbeck A/S
Phase 3
315
Edinburgh, Great Yarmouth, Glasgow, London
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Cambridge, Glasgow, Scotland, London, Sutton
2023-06-05
Recruiting
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
NCT05753930Kidney Transplantation in Highly Sensitized Patients
DrugImlifidase
Hansa Biopharma AB
Phase 2
10
London
2023-06-02
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
London, Manchester, Guildford, Sutton, Bebington
2023-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
London, Newcastle upon Tyne
2023-05-31
Recruiting
European Aortic Data Collection Project
NCT05896397Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection
Cook Research Incorporated
Observational
600
Birmingham, Bristol, London
2023-05-31
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
London, Oxford, Newcastle upon Tyne
2023-05-31
Active, closed
Amgen
Phase 3
509
London, Manchester
2023-05-31
Active, closed
ML Bio Solutions, Inc.
Phase 3
112
London, Newcastle upon Tyne
2023-05-31
Active, closed
Apellis Pharmaceuticals, Inc.
Phase 3
100
London, Manchester, Nottingham
2023-05-29
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Recruiting
A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
NCT05791864Neuronal Ceroid Lipofuscinosis Type 2
Tern Therapeutics, LLC
Phase 1/2
26
London
2023-05-17
Recruiting
Takeda
Phase 3
240
London, Cardiff, Birmingham, Manchester
2023-05-16
Recruiting
Life Detection Technologies
Observational
75
London
2023-05-15
Active, closed
Gilead Sciences
Phase 1
182
London, Sutton
2023-05-11
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Cardiff, London, Manchester
2023-05-08
Active, closed
Gilead Sciences
Phase 3
654
London, Manchester, Nottingham
2023-05-08
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
DrugsIvonescimab·Pemetrexed·Carboplatin
Summit Therapeutics
Phase 3
420
London, Manchester
2023-05-04
Active, closed
Creo Medical Limited
Observational
35
London
2023-05-04
Active, closed
Shockwave Medical, Inc.
Observational
399
Clydebank, Liverpool, London
2023-05-03
Recruiting
Vulvar Disease in Nigeria Observational Study
NCT05890092Vulvar Diseases, Vulvar Atrophy, Dermatoses
KDRS ltd
Observational
1,000
London
2023-05-03
Active, closed
Servier Affaires Médicales
Phase 3
299
Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne
2023-05-03
Recruiting
The Ailliance Post-Market Clinical Study
NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma
Medtronic Spinal and Biologics
Not applicable
1,000
London
2023-05-01
Recruiting
AbbVie
Phase 3
450
London, Gillingham, Aberdeen, Stockport
2023-05-01
Active, closed
OncoSil Medical Limited
Phase 2
88
London, Manchester, Newcastle upon Tyne, Southampton
2023-04-26
Active, closed
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Birmingham, Hull, London
2023-04-26
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Brighton, Lincoln, London, Londonderry, Newcastle, Newcastle upon Tyne, Plymouth, Worcester
2023-04-25
Active, closed
AstraZeneca
Phase 2
294
Cambridge, London, Manchester
2023-04-24
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
DrugApitegromab
Scholar Rock, Inc.
Phase 3
238
Leeds, London, Oxford
2023-04-17
Active, closed
Hoffmann-La Roche
Phase 2
204
London, Preston, Sutton
2023-04-13
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Bristol, Clydebank, Dorchester, Exeter, High Wycombe, Lincoln, London, Sheffield
2023-04-11
Active, closed
AstraZeneca
Phase 3
94
London, Manchester
2023-04-05
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Active, closed
GlaxoSmithKline
Phase 2
154
Leeds West Yorkshire, London, Sutton
2023-04-03
Active, closed
Sanofi
Phase 2
999
London, Edinburgh, Sheffield
2023-04-03
Active, closed
Bayer
Phase 3
985
London, Northwood, Guildford
2023-04-03
Recruiting
Eupraxia Pharmaceuticals Inc.
Phase 1/2
117
Norwich, Cardiff, Liverpool, London
2023-03-31
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Birmingham, Newcastle upon Tyne, Chelsea, Glasgow, London
2023-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Edinburgh, London, Plymouth, Scunthorpe, Sheffield, Stevenage, Truro
2023-03-23
Recruiting
AbbVie
Phase 1
210
London, Manchester
2023-03-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
East Sussex, Bristol, London, Crumpsall
2023-03-17
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Birmingham, Leeds, London
2023-03-16
Recruiting
Vega Therapeutics, Inc
Phase 1/2
116
Birmingham, Southampton, London, Whitechapel
2023-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
London, Sheffield
2023-03-16
Active, closed
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
DrugPYX-201
Pyxis Oncology, Inc
Phase 1
330
London
2023-03-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Bristol, London, Manchester
2023-03-08
Active, closed
GRIN Therapeutics, Inc.
Phase 1
24
Glasgow, London
2023-03-07
Active, closed
AstraZeneca
Phase 2
188
London, Nottingham
2023-03-06
Active, closed
Bristol-Myers Squibb
Phase 3
579
London, Headington, Oxford, Newcastle upon Tyne
2023-03-06
Recruiting
Takeda
Phase 3
160
Cambridge, Edinburgh, London, Nottingham, Plymouth
2023-03-06
Active, closed
Pfizer
Phase 3
624
London, Blackburn, Glasgow, Manchester
2023-03-03
Recruiting
Magseed Pro(R)/ Sentimag(R) Gen3
NCT05142787Breast Cancer
Endomagnetics Ltd.
Not applicable
224
London, Manchester
2023-03-02
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
NCT05797519Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
120
Brighton, London
2023-03-01
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Recruiting
Boehringer Ingelheim
Phase 1
66
London, Oxford, Sutton
2023-02-24
Recruiting
Fore Biotherapeutics
Phase 2
254
Manchester, London
2023-02-21
Active, closed
Gilead Sciences
Phase 2
400
London
2023-02-21
Active, closed
DBV Technologies
Phase 3
600
London, Manchester, Sheffield, Southampton
2023-02-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
553
East Sussex, Crumpsall, London, Newcastle upon Tyne, Birmingham
2023-02-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Active, closed
COMPASS Pathways
Phase 3
572
Bodmin, Chertsey, Chester, Doncaster, Exeter, Fulbourn, London, Newcastle
2023-02-14
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
London, Oxford
2023-02-14
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Belfast, Cardiff, London, Sheffield
2023-02-13
Recruiting
Beckley Psytech Limited
Phase 2
72
Liverpool, London
2023-02-10
Active, closed
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Recruiting
Medtronic Cardiovascular
Not applicable
400
Brighton, Leeds, London
2023-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Birmingham, London, Nottingham
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
London, Oxford
2023-02-02
Active, closed
Stryker Craniomaxillofacial
Observational
99
London
2023-02-01
Recruiting
Tenaya Therapeutics
Observational
200
Glasgow, London
2023-01-31
Active, closed
Areteia Therapeutics
Phase 3
600
Bellshill, Birmingham, Bollington, Chorley, Enfield, Liverpool, London, Manchester
2023-01-30
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Sheffield, London, Middlesbrough, Wolverhampton, Cambridge
2023-01-25
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Liverpool, London
2023-01-24
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
London
2023-01-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2
42
London
2023-01-19
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Cambridge, London, Bury, Harrow, Yeovil, Huddersfield
2023-01-16
Recruiting
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Recruiting
Forma Therapeutics, Inc.
Phase 2
95
London, Manchester
2023-01-12
Recruiting
OSTEOMICS: Identifying Regulators of Bone Homeostasis
NCT05732870Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
Relation Therapeutics
Observational
2,000
London
2023-01-12
Active, closed
Bristol-Myers Squibb
Phase 3
513
London, Central Middlesbrough, Oxford
2023-01-12
Active, closed
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560Mitral Stenosis, Mitral Valve Insufficiency
Edwards Lifesciences
Observational
504
Cambridge, London
2023-01-11
Active, closed
Daiichi Sankyo
Phase 3
1,170
London
2023-01-11
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Exemestane·Everolimus·Abemaciclib
Ellipses Pharma
Phase 1/2
95
London, Manchester, Liverpool
2023-01-11
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
London
2023-01-11
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
London, Newcastle upon Tyne, Oxford
2023-01-06
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Nottingham, Cannock, London, Manchester, Newcastle upon Tyne
2023-01-02
By invitation
BioMarin Pharmaceutical
Observational
172
Cambridge, Glasgow, London, Oxford, Southampton
2023-01-01
Active, closed
Exelixis
Phase 3
317
Sheffield, London
2023-01-01
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Birmingham, Leeds, London
2022-12-30
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton
2022-12-29
Active, closed
Ipsen
Phase 2
68
Aberdeen, Birmingham, Frimley, Glasgow, Hull, London
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
London
2022-12-28
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton
2022-12-23
Active, closed
Novartis Pharmaceuticals
Phase 3
20
London, Newcastle upon Tyne
2022-12-19
Recruiting
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Recruiting
H. Lundbeck A/S
Phase 1/2
42
Birmingham, Cambridge, London
2022-12-19
Active, closed
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459Amyotrophic Lateral Sclerosis
QurAlis Corporation
Phase 1
69
Sheffield, London
2022-12-16
Recruiting
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Recruiting
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Active, closed
Hemab ApS
Phase 1/2
57
Birmingham, Leeds, London, Whitechapel
2022-12-13
Recruiting
Pharming Technologies B.V.
Phase 2
180
Cambridge, London, Newcastle
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Recruiting
Gilead Sciences
Phase 3
1,514
Cottingham, Edgbaston, Liverpool, London, Manchester, Northwood, Taunton, York
2022-12-12
Recruiting
Pfizer
Phase 3
100
Newcastle upon Tyne, Birmingham, London, Manchester
2022-12-09
Active, closed
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
By invitation
Allievex Corporation
Phase 4
15
London
2022-12-02
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
25,000
London
2022-12-02
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Bellshill, Edgbaston, Manchester, Cardiff, Hampstead, Liverpool, London
2022-11-30
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
London, Oxford
2022-11-29
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
Sanofi
Phase 2
187
Cambridge, London, Warrington
2022-11-25
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
DrugRamantamig
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Liverpool, London, Oxford, Sheffield
2022-11-21
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Glasgow, Gloucester, London, Newport
2022-11-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
48
London
2022-11-16
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
London
2022-11-10
Recruiting
Bayer
Phase 3
100
London, Manchester, Nottingham, Glasgow
2022-11-08
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Active, closed
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Active, closed
QBiotics Group Limited
Phase 2
15
Cardiff, Stevenage, Bebington, London
2022-11-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Airdrie, Leeds, London
2022-10-28
Active, closed
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.
Phase 1/2
7
Glasgow, London
2022-10-26
Active, closed
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
136
Cambridge, London
2022-10-25
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
London, Sutton
2022-10-25
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Active, closed
Almirall, S.A.
Phase 4
447
London, Oxford, Poole, Weston-super-Mare
2022-10-24
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
London, Liverpool, Glasgow, Redhill, Aberdeen
2022-10-14
Active, closed
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)
NCT05981092Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)
Alexion Pharmaceuticals, Inc.
Observational
35
Harefield, London
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
Gilead Sciences
Phase 3
1,021
London, Manchester
2022-10-12
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Active, closed
Janssen Research & Development, LLC
Phase 1
196
London, Manchester, Oxfordshire
2022-10-04
Active, closed
Eli Lilly and Company
Phase 3
8,000
Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth
2022-10-04
Recruiting
Ellipses Pharma
Phase 1/2
265
London, Manchester, Sheffield
2022-09-30
Recruiting
Aymes International Limited
Not applicable
40
London
2022-09-30
Active, closed
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Hull, London, Newcastle upon Tyne, Salford
2022-09-27
Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
NCT04757116Benign Prostatic Hyperplasia (BPH)
Olympus Corporation of the Americas
Not applicable
256
Isleworth, Dunfermline, London, Norwich
2022-09-26
Recruiting
Xiros Ltd
Observational
58
Canterbury, London, Nottingham, Reading
2022-09-26
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Birmingham, Devon, Glasgow, London, Sheffield
2022-09-23
Active, closed
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Recruiting
Pfizer
Phase 2/3
389
Bristol, London
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Bath, Bristol, Essex, Glasgow, London, Oxford
2022-09-22
Recruiting
Celgene
Phase 3
810
Cambridge, Truro, London, Airdrie, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Active, closed
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford
2022-09-19
Active, closed
Vir Biotechnology, Inc.
Phase 2
95
Birmingham, London, Manchester
2022-09-17
Active, closed
Biogen
Phase 2/3
450
London, Manchester, Birmingham, Leeds
2022-09-13
Active, closed
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Active, closed
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Recruiting
AstraZeneca
Phase 2
454
Cambridge, Dundee, London, Manchester
2022-09-06
Active, closed
Dyne Therapeutics
Phase 1/2
127
London, Newcastle upon Tyne, Salford
2022-09-05
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Headington, London, Metropolitan Borough of Wirral
2022-09-05
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Active, closed
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT04711135Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera
Advanced Accelerator Applications
Phase 2
11
London
2022-08-31
Recruiting
Stemline Therapeutics, Inc.
Phase 1/2
73
Leicester, Liverpool, London, Manchester
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
London, Oxford
2022-08-30
Recruiting
Novartis Pharmaceuticals
Phase 2
42
London, Stoke-on-Trent
2022-08-29
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Birmingham, Cambridge, London
2022-08-26
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
Adverum Biotechnologies, Inc.
Phase 2
69
London, Oxford
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
By invitation
argenx
Phase 2/3
12
London, Oxford
2022-08-18
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
London, Manchester, Northwood, Preston
2022-08-17
Recruiting
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
Gilead Sciences
Phase 2/3
689
Birmingham, Brighton, London
2022-08-16
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
London, Manchester
2022-08-12
Active, closed
Dyne Therapeutics
Phase 1/2
86
Liverpool, Newcastle upon Tyne, Leeds, Bristol, London
2022-08-12
Active, closed
Novo Nordisk A/S
Phase 3
412
Cambridge, Hull, Liverpool, London, Manchester, Tooting
2022-08-10
Active, closed
Mercator MedSystems, Inc.
Phase 2
60
London
2022-08-08
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Aberdeen, London, Plympton
2022-08-08
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Recruiting
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
AstraZeneca
Phase 3
341
London, Manchester, Wolverhampton
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Leeds, London
2022-08-03
Active, closed
Genentech, Inc.
Phase 3
373
Manchester, Dorchester, London, Nottingham
2022-08-03
Active, closed
Gilead Sciences
Phase 3
443
Edinburgh, Glasgow, Leeds, London, Nottingham
2022-07-25
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Bristol, Leicester, London, Swansea
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Active, closed
Denali Therapeutics Inc.
Phase 2/3
65
London, Birmingham, Salford
2022-07-21
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Active, closed
Gilead Sciences
Phase 3
623
Leeds, London
2022-07-20
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Colchester, Edinburgh, London, Maidstone
2022-07-20
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
Hoffmann-La Roche
Phase 3
922
Bath, Blackpool, Cleveland, London, Maidstone, Nottingham, Preston, Rhyl
2022-07-18
Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Observational
150
London
2022-07-14
Active, closed
GlaxoSmithKline
Phase 3
163
Birmingham, Cambridge, London
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Bradford, London
2022-07-14
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
154
Birmingham, Bristol, London
2022-07-13
By invitation
Gyroscope Therapeutics Limited
Phase 2
225
London, Sunderland
2022-07-12
Active, closed
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
Incyte Corporation
Phase 1
291
London, Newcastle upon Tyne
2022-07-05
Recruiting
Octapharma
Phase 3
38
London
2022-07-01
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
London
2022-06-30
Recruiting
IntraBio Inc
Phase 3
53
London, Manchester
2022-06-30
Active, closed
Corcept Therapeutics
Phase 3
381
Brighton, Taunton, Cheltenham, London, Manchester, Northwood
2022-06-29
Recruiting
Orphalan
Observational
500
Leeds, London
2022-06-29
Active, closed
Cogent Biosciences, Inc.
Phase 2
237
London
2022-06-27
Recruiting
AstraZeneca
Phase 1/2
695
Glasgow, Scotland, London, Newcastle upon Tyne
2022-06-24
Active, closed
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Active, closed
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Active, closed
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Recruiting
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA
Phase 1/2
304
Cambridge, Liverpool, London, Oxford, Warrington
2022-06-21
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
210
Cardiff, London
2022-06-21
Active, closed
Hoffmann-La Roche
Phase 4
136
London, Manchester
2022-06-20
Active, closed
ADC Therapeutics S.A.
Phase 1
154
London, Oxford
2022-06-17
Recruiting
BioNTech SE
Phase 1
320
Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne
2022-06-17
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
By invitation
Biogen
Phase 3
864
London, Doncaster, Cannock
2022-06-10
Recruiting
Nuvalent Inc.
Phase 1/2
840
Sutton, Edinburgh, London, Manchester
2022-06-09
Active, closed
Agios Pharmaceuticals, Inc.
Phase 3
49
London
2022-06-08
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Recruiting
Perspectum
Observational
1,000
Didcot, Eynsham, Farringdon, Witney, Redhill, Baglan, Liverpool, London
2022-05-30
Active, closed
Gilead Sciences
Phase 2
193
Birmingham, London
2022-05-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Birmingham, London
2022-05-30
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
London, Manchester, Newcastle upon Tyne
2022-05-23
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Glasgow, London, Manchester
2022-05-22
Recruiting
Electra Therapeutics Inc.
Phase 2/3
156
London
2022-05-19
Active, closed
IO Biotech
Phase 3
407
London, Manchester, Oxford
2022-05-17
Active, closed
AbbVie
Phase 1
34
London
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Recruiting
Hoffmann-La Roche
Phase 2
40
Glasgow, Liverpool, London
2022-05-12
Recruiting
Innovacell GmbH
Phase 3
290
London
2022-05-11
Active, closed
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
Hanmi Pharmaceutical Company Limited
Phase 2
17
London, Manchester
2022-05-05
Active, closed
Sanofi
Phase 3
104
London
2022-05-03
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Glasgow, Cambridge, London, Manchester, Merseyside
2022-05-03
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
16
London
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
13
London
2022-05-02
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
London
2022-04-27
Recruiting
First in Human Study of T3P-Y058-739 (T3P)
NCT05120596Advanced Solid Tumor
DrugPembrolizumab
T3 Pharmaceuticals AG
Phase 1/2
100
Glasgow, Leeds, London, Southampton
2022-04-26
By invitation
AstraZeneca
Phase 3
214
London, Sheffield
2022-04-19
Active, closed
Sanofi
Phase 3
43
London
2022-04-18
Active, closed
Eli Lilly and Company
Phase 3
925
Blackburn, Colchester, London
2022-04-14
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Cambridge, Glasgow, London, Manchester, Sheffield
2022-04-14
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Active, closed
CONVERGE Post-Approval Study (PAS)
NCT05393180Chronic Atrial Fibrillation
AtriCure, Inc.
Not applicable
53
London
2022-04-13
Active, closed
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
Recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NCT04493632Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
OncoSil Medical Limited
Observational
500
London
2022-04-12
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Uxbridge, Barnet, Boston, Harrow, London, Oxford
2022-04-11
Recruiting
Zimmer Biomet
Observational
500
Edinburgh, Leeds, London
2022-04-11
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Leicester, London
2022-04-05
Active, closed
Geko™ Cross Therapy Registry - Wound
NCT05007301Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Firstkind Ltd
Observational
2,500
London, Norwich
2022-04-04
Active, closed
Precise Procedural and PCI Plan (P4)
NCT05253677Coronary Artery Disease
CoreAalst BV
Not applicable
1,090
Poole, Clydebank, Liverpool, London, Newcastle
2022-04-01
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 2/3
522
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
London, Leeds
2022-03-29
Active, closed
Bayer
Phase 3
219
London, Manchester, Nottingham, Glasgow
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Recruiting
MicroPort CRM
Observational
206
Basildon, London, Westcliff-on-Sea
2022-03-25
Recruiting
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Novo Nordisk A/S
Phase 3
153
Birmingham, Bristol, London
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
Sanofi
Phase 3
122
Cambridge, London, Salford
2022-03-11
Active, closed
BeOne Medicines
Phase 3
799
Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton
2022-03-10
Active, closed
Rocket Pharmaceuticals Inc.
Observational
9
London
2022-03-09
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Bristol, London, Manchester, Sheffield
2022-03-08
Recruiting
Pfizer
Phase 3
160
London
2022-03-07
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
London, Sutton, Manchester
2022-03-07
Recruiting
Occlutech International AB
Observational
50
London
2022-03-03
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
18
Salford, London
2022-03-03
Active, closed
Janssen Research & Development, LLC
Phase 2
151
Leicester, London
2022-03-01
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 3
86
London
2022-02-14
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2/3
286
London, Cambridge, Manchester
2022-02-11
Recruiting
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Manchester, Glasgow, London
2022-02-03
By invitation
Rocket Pharmaceuticals Inc.
Observational
14
London
2022-02-01
Rows per page Showing 1001–1500 of 2026
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=3

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 07 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,026 of those studies with a site in London.

How many clinical trials are recruiting in London?

983 of the 2,026 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:15 UTC sync. A further 26 have not yet opened recruitment, 956 are active but closed to new participants, and 61 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.